RPRX Royalty Pharma PE ratio, current and historical analysis
The price-to-earnings ratio for Royalty Pharma stock stands at 17.41 as of Feb 21, 2025. This is based on the current EPS of $1.92 and the stock price of $33.42 per share. An increase of 19% has been recorded in the PE ratio compared to the average of 14.7 of the last four quarters.
RPRX PE ratio history
Over the last five years, the average PE ratio of Royalty Pharma has been 46.54. The current 17.41 P/E ratio is 63% lower than the historical average. In the past five years, RPRX's PE ratio peaked in the Dec 2022 quarter at 395.2, with a price of $39.52 and an EPS of $0.1. The Sep 2020 quarter marked the lowest point at 7, with a price of $42.07 and an EPS of N/A.
Royalty Pharma PE ratio by year
Maximum annual increase: 1,377.94% in 2022
Maximum annual decrease: -97.2% in 2023
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 13.29 | 20.16% | $25.51 | $1.92 |
| 2023 | 11.06 | -97.2% | $28.09 | $2.54 |
| 2022 | 395.2 | 1,377.94% | $39.52 | $0.1 |
| 2021 | 26.74 | -29.48% | $39.85 | $1.49 |
| 2020 | 37.92 | N/A | $50.05 | $1.32 |
| 2019 | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A |
Royalty Pharma PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 13.29 | 20.71% | $25.51 | $1.92 |
| Sep 2024 | 11.01 | -36.94% | $28.29 | $2.57 |
| Jun 2024 | 17.46 | 2.89% | $26.37 | $1.51 |
| Mar 2024 | 16.97 | 53.44% | $30.37 | $1.79 |
| Dec 2023 | 11.06 | -84.11% | $28.09 | $2.54 |
| Sep 2023 | 69.59 | 24.51% | $27.14 | $0.39 |
| Jun 2023 | 55.89 | 14.79% | $30.74 | $0.55 |
| Mar 2023 | 48.69 | -87.68% | $36.03 | $0.74 |
| Dec 2022 | 395.2 | 1,021.13% | $39.52 | $0.1 |
| Sep 2022 | 35.25 | -11.12% | $40.18 | $1.14 |
| Jun 2022 | 39.66 | 46.56% | $42.04 | $1.06 |
| Mar 2022 | 27.06 | 1.2% | $38.96 | $1.44 |
| Dec 2021 | 26.74 | 43.53% | $39.85 | $1.49 |
| Sep 2021 | 18.63 | 13.18% | $36.14 | $1.94 |
| Jun 2021 | 16.46 | -43.4% | $40.99 | $2.49 |
RPRX average PE ratio chart
Currently, RPRX's PE ratio is lower than the 3-year average.
RPRX PE vs peers
RPRX's PE ratio stands lower than its peer stocks LLY and ABT.
| Stock name | PE ratio | Market cap |
|---|---|---|
| RPRX Royalty Pharma plc | 17.41 | $19.27B |
| ABT Abbott Laboratories | 40.88 | $234.01B |
| LLY ELI LILLY & Co | 74.29 | $828.4B |
| ANIP Ani Pharmaceuticals Inc | N/A | $1.22B |
Frequently asked questions
What is Royalty Pharma's PE ratio?
The price to earnings ratio for RPRX stock as of Feb 21, 2025, stands at 17.41.
What is the 3-year average PE ratio for Royalty Pharma (RPRX)?
The 3-year average price to earnings ratio for RPRX stock is 61.76.
What is the highest PE ratio for RPRX?
The highest quarterly PE ratio in the last five years has been 395.2 and it was in the Dec 2022 quarter.
How does the current PE ratio for RPRX compare to its historical average?
RPRX's current price to earnings ratio is 63% below its 5-year historical average.
How is RPRX's PE ratio calculated (Royalty Pharma PE ratio formula)?
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Feb 21, 2025), Royalty Pharma's stock price is $33.42. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $1.92. Therefore, Royalty Pharma's PE ratio for today is 17.41. PE RATIO(17.41) = STOCK PRICE($33.42) / TTM EPS($1.92)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.